Association of periprocedural intravenous morphine use on clinical outcomes in ST‐elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention: Systematic review and meta‐analysis
- 26 October 2019
- journal article
- review article
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 96 (1) , 76-88
Abstract
Objectives: To conduct a systematic review and meta‐analysis of studies examining the impact of periprocedural intravenous morphine on clinical outcomes in patients undergoing primary percutaneous coronary intervention (PCI) for ST‐elevation myocardial infarction (STEMI).Background: Morphine analgesia may reduce the absorption of co‐prescribed P2Y12 antagonists attenuating platelet inhibition. The impact of periprocedural intravenous morphine on clinical outcomes in patients undergoing PCI for STEMI is not well defined.Methods: Analysis of the electronic databases of MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), Scopus, Web of Science and ClinicalTrials.gov for association of peri‐PCI intravenous morphine use with in‐hospital or 30‐day myocardial infarction (MI) (primary outcome) and in‐hospital or 30‐day mortality.Results: A total of 11 studies were included for systematic review. One study was a randomized controlled trial, 10 were observational studies. Five studies including 3,748 patients were included in meta‐analysis of in‐hospital or 30‐day MI. Within this group, patients were treated concurrently with ticagrelor (n = 2,239), clopidogrel (n = 1,256) and prasugrel (n = 253). There was no significant association of in‐hospital or 30‐day MI with intravenous morphine (odds ratio 1.88; 95% confidence interval [CI] 0.87–4.09; I2 0%). Across seven studies and 5,800 patients, no increased risk of mortality at the same composite time endpoint was evident (odds ratio 0.70; 95% CI 0.40–1.23; I2 19%).Conclusions: Periprocedural intravenous morphine administration was not associated with adverse short‐term clinical outcomes in patients undergoing primary PCI for STEMI. Further randomized trial data are needed to evaluate the pharmacologic interaction between morphine and P2Y12 antagonists with clinical outcomes.Keywords
This publication has 27 references indexed in Scilit:
- Comparison of Prasugrel and Ticagrelor Loading Doses in ST-Segment Elevation Myocardial Infarction PatientsJACC, 2013
- ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevationEuropean Heart Journal, 2012
- Effect of age and gender on pharmacokinetics and pharmacodynamics of a single ticagrelor dose in healthy individualsEuropean Journal of Clinical Pharmacology, 2012
- Effect of Narcotic Treatment on Outcomes of Acute Coronary SyndromesThe American Journal of Cardiology, 2010
- Opioid receptors in the gastrointestinal tractRegulatory Peptides, 2009
- Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarctionThrombosis Research, 2008
- ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial InfarctionJACC, 2007
- Association of intravenous morphine use and outcomes in acute coronary syndromes: Results from the CRUSADE Quality Improvement InitiativeAmerican Heart Journal, 2005
- Opioids and cardioprotectionPharmacology & Therapeutics, 2001
- INTRAVENOUS MORPHINE IN CORONARY THROMBOSIS.The Lancet, 1930